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Abstract
Background: Bevacizumab and irinotecan may represent one of the most active treatments in progressive malignant glioma. 
Limited published experience with bevacizumab in patients with CNS tumors raises concerns regarding toxicity, particularly 
in regards to hemorrhage and thromboembolism.
Methods: We retrospectively reviewed 36 patients with progressive malignant glioma after prior resection, chemotherapy 
and radiation who were treated with bevacizumab at our institution. Patients were evaluated for bevacizumab-related adverse 
events, time to treatment failure (TTF) and overall survival (OS). Two patients who progressed or died prior to completion 
of 4 cycles of therapy were analyzed for adverse events only.
Results: Patients were treated with bevacizumab alone (1), bevacizumab plus irinotecan (31), or bevacizumab plus carbo-
platin (4). In 34 patients who received >4 cycles of bevacizumab, median TTF and OS were 16 and 32 weeks, respectively. 
Toxicities included 1 arterial thrombosis, 4 venous thromboses, and 3 clinically signiﬁ  cant CNS hemorrhages.
Conclusion: Overall, our results conﬁ  rm the efﬁ  cacy and safety of bevacizumab in combination with chemotherapy in 
patients with progressive malignant glioma. Although the TTF and OS were less than previously reported with the combi-
nation of bevacizumab and irinotecan, this was an unselected patient population with 50% of patients having received >1 
prior chemotherapy regimen.
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Introduction
Malignant glioma is a devastating disease with median survival of approximately one year for grade 
IV glioblastoma multiforme (GBM) and three years for grade III anaplastic astrocytoma (AA). The 
prognosis of patients with recurrent or progressive malignant glioma is extremely poor. Repeat surgery 
or radiotherapy is often precluded by the morbidity of these interventions, and chemotherapy has lim-
ited efﬁ  cacy. The median survival of patients with recurrent GBM or AA who are enrolled in phase II 
chemotherapy trials is just 30 weeks and survival is likely lower in patients who are ineligible for trials 
at the time of their recurrence (Wong et al. 1999). Given the lack of effective therapeutic options, there 
is no universally accepted standard of care for recurrent malignant glioma, and patients are encouraged 
to participate in clinical trials evaluating new agents.
Prior to 2005, the standard of care for the primary treatment of malignant gliomas was surgical 
resection followed by radiotherapy. The beneﬁ  t of nitrosourea-based chemotherapy was unproven in 
randomized prospective trials, although a meta-analysis from 12 randomized trials showed an increase 
in one year survival from 40% to 46% with chemotherapy (Stewart, 2002). The standard of care for 
newly diagnosed GBM was modiﬁ  ed in 2005 to include the non-classical alkylating agent, temozolo-
mide, as adjuvant and concomitant therapy with external beam radiotherapy. This treatment protocol 
increases median survival from 12.1 months with radiotherapy alone to 14.6 months with the combina-
tion of radiotherapy and temozolomide (Stupp et al. 2005). Despite the overall survival beneﬁ  t from 456
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the addition of temozolomide to radiotherapy, 90% 
of patients developed progressive disease by 
24 months.
In view of the poor prognosis of glioma patients 
despite treatment with conventional chemotherapy, 
interest has turned towards the combination of 
targeted therapies with chemotherapy. Malignant 
gliomas are highly vascularized and thus angio-
genesis inhibitors are being actively explored in 
these tumors. VEGF has been found to be impor-
tant in the development of abnormal vasculature 
seen in malignant gliomas (Plate et al. 1992; 
Chaudhry et al. 2001). Tumors with increased 
vascular proliferation tend to be more aggressive 
and the extent of vascularization corresponds with 
prognosis (Leon et al. 1996; Birner et al. 2003). 
Bevacizumab is a monoclonal antibody to VEGF, 
which prevents interaction with VEGF receptors 
on the cell surface. Bevacizumab has been 
approved for use in combination with chemotherapy 
in metastatic colon, breast, and lung cancer (Miller 
et al. 2007; Giantonio et al. 2006; Ramalingam 
et al. 2008; Sandler et al. 2006). In malignant 
gliomas, bevacizumab (10 mg/kg) has been evalu-
ated in combination with irinotecan (125mg/m
2, 
or 340mg/m
2 in patients on EIAEDs, enzyme 
inducing anti-epileptic drugs) with cycles given 
every two weeks (Vredenburgh et al. 2007a; 
Vredenburgh et al. 2007b). Early clinical experi-
ence with this regimen in GBM has been promis-
ing, with a phase II study of thirty-ﬁ  ve recurrent 
GBM patients showing a median progression-free 
survival of 24 weeks and median overall survival 
of 42 weeks (Vredenburgh, 2007b). Thrombotic 
events were noted, though risk of CNS hemorrhage 
was minimal. These results have demonstrated the 
efﬁ  cacy and safety of bevacizumab in combination 
with irinotecan in a small number of patients with 
malignant glioma. Bevacizumab seems to be well 
tolerated and response rates are amongst the high-
est ever reported in this population. Validation in 
a larger study is pending and toxicity data are 
limited. Over the past 24 months, we have used 
bevacizumab-based salvage chemotherapy in 
patients with recurrent or progressive gliomas at 
our institution and report our experience herein.
Methods
We performed a retrospective analysis of patients 
treated at our institution between December 2005 
and December 2007 with bevacizumab-based 
salvage therapy, after prior standard therapy for 
progressive malignant glioma. Patients had to have 
histopathologic evidence of an inﬁ  ltrative glioma 
and radiographic evidence of malignant tumor 
progression (enlarging area of nodular contrast 
enhancement). Failure of standard of care therapy 
(radiation, temozolomide) had to be documented. 
Patients eligible for a clinical trial available at our 
institution were treated with bevacizumab-based 
salvage therapy only if they were not interested in 
participating in the trial. Patients were evaluated 
for bevacizumab-related adverse events, time to 
treatment failure (TTF), and overall survival (OS). 
Overall survival was determined based on ﬁ  rst date 
of treatment with this regimen until date of death 
from any cause. In two patients, the exact date 
of death was unknown and the date of last corre-
spondence was used. TTF was determined based 
on ﬁ  rst date of treatment with this regimen until 
progression, death, unacceptable toxicity or patient 
decision to withdraw from treatment. Median times 
and confidence intervals were calculated by 
SigmaPlot
® statistics program. Two patients who 
progressed or died prior to completion of four 
cycles of bevacizumab were analyzed for adverse 
events only. The bevacizumab dose ranged from 
5–10 mg/kg, typically given every two weeks. The 
second agent was irinotecan at 100–200mg/m
2 (up 
to 340mg/m
2 on patients on EIAEDs) or carbopla-
tin with AUC of 5–6. Hemorrhage that led to new 
symptoms, decline in status, or hospitalization 
were considered clinically significant (as per 
CTCAE 3.0 grading of adverse events, 2006) as 
opposed to hemorrhage found incidentally on 
restaging studies.
Results
In thirty-six patients treated with bevacizumab-
based regimens, the median age was 50 (range 
24–76). Twenty-two patients had progressive GBM 
and fourteen patients had other progressive gliomas, 
including: grade III oligodendroglioma (4), grade 
III astrocytoma (4), grade III ependyoma (1), grade 
III mixed glioma (1) and grade II glioma with clear 
evidence of progression (4). In four patients, pro-
gression from grade II to grade III or IV was pre-
sumed based on imaging and clinical status even 
though a biopsy was not repeated at the time of 
progression. The other thirty-two had biopsy proven 
malignant glioma. All patients had received prior 
radiotherapy and temozolomide. Eighteen patients 457
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(50%) had received temozolomide only, and 
eighteen (50%) had received temozolomide and 
other salvage treatments as follows: AZD2171 
(cediranib), ST1481 (gimatecan), erlotinib/rapamy-
cin, imatinib/hydroxyurea, thalidomide/temozolo-
mide/celebrex, IL-13 pseudomonas exotoxin, PCV, 
and high dose carboplatin/etoposide with autolo-
gous stem cell transplant. Twenty-two percent of 
patients had already undergone at least three prior 
chemotherapies.
Thirty-six patients were treated with bevaci-
zumab-based regimens as follows: bevacizumab 
alone (1), bevacizumab and irinotecan (31), and 
bevacizumab and carboplatin (4). Thirty-four 
received ≥4 cycles of bevacizumab (median 8, 
range of 4–23 cycles), and were included in efﬁ  -
cacy analysis. The median TTF was 16 weeks 
[14.2–17.8, 95% C.I.] with a range of 7–82 
weeks (See Fig. 1). The median OS was 32 weeks 
[27.2–36.6, 95% C.I.] with a range of 10–82 weeks 
(See Fig. 2). The progression free survival at 
6 months was 25%. Six patients were still being 
actively treated at the time of this analysis.
Review of the adverse events in the thirty-six 
patients revealed one arterial thrombotic event, 
speciﬁ  cally myocardial infarction (2.8%), four 
venous thrombotic events (11.1%), and ﬁ  ve intra-
cranial hemorrhages, of which only three were 
clinically significant (8.3%). There was also 
one non-clinically signiﬁ  cant intracranial hemor-
rhage one month after the last treatment.
Discussion
Many of our patients were previously on clinical 
trials and were not eligible for additional trials at 
the time of their bevacizumab therapy. Their treat-
ment options were extremely limited. A meta-
analysis of eight phase II chemotherapy trials in 
375 patients with recurrent GBM and AA after 
radiotherapy found an overall progression free 
survival at 6 months of 21% (15% for GBM, 20% 
for AA), median progression free survival of 
10 weeks and median overall survival of 30 weeks 
(Wong, 1999). In this analysis, one trial excluded 
patients with any previous chemotherapy and two 
trials excluded patients with more than one previ-
ous chemotherapy regimen. The overall survival 
in our patients was similar to that reported in 
patients being enrolled in chemotherapy clinical 
trials.
The two published phase II studies with beva-
cizumab in combination with irinotecan have 
raised the possibility that this combination may 
represent the most active regimen in progressive 
malignant gliomas (Vredenburgh et al. 2007a; 
Vredenburgh et al. 2007b). The ﬁ  rst of these studies 
included 32 patients with recurrent malignant 
gliomas (23 grade IV, 9 grade III lesions) 
(Vredenburgh et al. 2007a). The median PFS was 
23 weeks for all (20 weeks for grade IV and 30 for 
grade III). Toxicities in this group of patients 
included three venous thrombotic events, one 
Figure 1. Kaplan-Meier for time to treatment failure. Figure 2. Kaplan-Meier for overall survival.458
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arterial ischemic stroke and no CNS hemorrhages. 
The results for patients with GBM only were 
reported separately with an additional 12 patients, 
demonstrating PFS of 24 weeks and median sur-
vival of 42 weeks in this subset of 35 patients 
(Vredenburgh et al. 2007b). In this group, four 
venous thrombotic events and one CNS hemor-
rhage were observed.
The median TTF of 16 weeks in our series was 
lower than that of 23–24 weeks reported in the 
published phase II studies with irinotecan and 
bevacizumab. This may reﬂ  ect patient selection, 
as 50% of the patients in our series had received 
prior salvage therapy after failing temozolomide, 
including eight (22%) patients who had received 
three or more prior regimens. Our results were 
similar to or better than trials with other experi-
mental targeted therapies in patients with progres-
sive gliomas. One of the more promising of these 
agents is cediranib (AZD2171), an oral VEGF and 
PDGF receptor TK inhibitor which has been shown 
to normalize vasculature in patients with recurrent 
glioblastoma (Batchelor et al. 2007a). In a phase 
II trial of AZD2171 in recurrent GBM, the 6 month 
PFS was 27.6%, median PFS was 16 weeks, and 
median overall survival was 32 weeks (Batchelor 
et al. 2007b).
Numerous other agents are being tested includ-
ing vatalanib, vorinostat, lenalidomide, erlotinib, 
and enzastaruin and preliminary data shows limited 
activity (Fine et al. 2007; Galanis et al. 2007; 
Cloughesy et al. 2005; Conrad et al. 2004; Reardon 
et al. 2004; Fine et al. 2005). Published phase II 
data is available on imatinib, thalidomide, geﬁ  tinib 
and temsirolimus. Treatment with imatinib mesyl-
ate, which is an inhibitor of multiple tyrosine 
kinase inhibitors including PDGFR, in combina-
tion with hydroxyurea, was found have a median 
progression-free survival (PFS) of 14.4 weeks and 
PFS at 6 months of 27% in patients with recurrent 
GBM (Reardon et al. 2005). Thalidomide has also 
been evaluated for its anti-angiogenic properties. 
As a single agent, thalidomide was found to have 
a median survival of 31 weeks and 6 month PFS 
of 18% in patients with recurrent glioblastoma 
(Marx et al. 2001). In patients with recurrent high 
grade gliomas, the median TTP was 10 weeks with 
a median overall survival of 28 weeks (Fine et al. 
2000). In combination with carmustine, thalido-
mide was found to have 6 month PFS of 27% and 
median PFS of 14 weeks (Fine et al. 2003). Single 
agent geﬁ  tinib produced a median TTP of 8.4 
weeks and median OS of 24.6 weeks, with a 
14% PFS at 6 months (Franceschi et al. 2007). 
Temsirolimus was not found to have signiﬁ  cant 
efﬁ  cacy, with a median time to progression of 
9–10 weeks in patients with recurrent GBM 
(Galanis et al. 2005; Chang et al. 2005). Of all 
these studies, none of the agents showed efﬁ  cacy 
as impressive as that published with irinotecan and 
bevacizumab. However, there is considerable con-
cern about the potential toxicities of using bevaci-
zumab in the glioma population.
Bevacizumab causes mild mucosal bleeding and 
has been associated with life-threatening pulmo-
nary hemorrhage in a subset of patients with lung 
cancer, raising concerns about risk of intra-cranial 
hemorrhage in patients with gliomas (Sandler et al. 
2006). Studies with bevacizumab in patients with 
various types of cancer have excluded patients with 
brain metastases given concern over risk of CNS 
bleeds (Sandler et al. 2006; Hurwitz et al. 2005). 
Our study found clinically signiﬁ  cant hemorrhages 
in three patients (8%). Two of these hemorrhages 
were in patients on anticoagulation with either low 
molecular weight heparin or warfarin. Our patients 
clearly had more toxicity in terms of hemorrhage 
compared with previously reported data with 
bevacizumab, but 8 (22%) of our patients were on 
anticoagulation whereas the previously published 
study excluded patients who were on anticoagulation 
(Vredenburgh et al. 2007a). In addition, those that 
developed need for anticoagulation during treat-
ment with bevacizumab were taken off study 
(Vredenburgh et al. 2007a). Patients with baseline 
hemorrhage on MRI were excluded in the previous 
study, though it is not clear if patients with history 
of prior hemorrhage were excluded. One of the 
patients treated at our institution who developed 
CNS hemorrhage had a history of hemorrhage at 
presentation two years prior. Glioblastomas are 
known to have a signiﬁ  cant risk of hemorrhage. 
The incidence of spontaneous intracranial hemor-
rhage in patients with gliomas ranges from 6.2%–
8.7% (Wakai et al. 1982; Kondziolka et al. 1987; 
Lieu et al. 1999). In addition to hemorrhage, con-
cerns have also been raised about craniotomy site 
dehiscence in patients treated with bevacizumab 
(Chamberlain, 2008). In our review, two patients 
were noted to have delayed wound healing after 
port placement but otherwise no wound issues were 
noted.
Overall, our results have demonstrated clinical 
efﬁ  cacy of bevacizumab-based regimens in patients 459
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with progressive malignant gliomas. This was an 
unselected patient population with 50% of patients 
having received more than one prior regimen, some 
with previous antiangiogenic agents. Thus it is not 
surprising that our TTF and OS are less than that 
seen in the two published studies with bevacizumab 
and irinotecan. We observed no unusual or excessive 
toxicities of bevacizumab in these patients. Finally, 
our experience supports the prior observation that 
bevacizumab does not substantially increase the risk 
of intracranial bleed above the baseline risk of bleeds 
in these tumors, though one should use caution in 
patients requiring anticoagulation.
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